The biomedical textiles market is projected to be worth $14.5 billion by 2022, growing from its 2017 value of $10.99 billion, according to a report from MarketsandMarkets.
The rising number of surgeries, growing number of elderly people in the population, the high quality of biomedical textiles, and a growing need for advanced wound dressing materials are said to be significant factors in driving this expected growth.
The report noted the following segments as leaders in the growth of the market:
- Non-biodegradable fibers, which includes polypropylene, polyethylene, viscose, polyamide and polyester in various applications, such as bandages, surgical sutures, soft and hard tissue implants and extracorporeal devices.
- Non-implantable biomedical textile applications include wound care products such as adhesive, cohesive, tubular, triangular and other types of bandages.
- Nonwoven biomedical textiles applications include light support, bandages, artificial skin, orthopedic implants, plaster, gauzes and others. These fabrics offer absorption, softness, smoothness, strength, stretchability, comfort, fit and cost-effectiveness.
The Asia Pacific region is expected to be the fastest growing market in this time period. The emerging markets of APAC, such as China, India and Singapore, are noted to have increasing health care expenditures and rising disposable income, triggering growth in the sector.
The report says that key players operating in the biomedical textiles market include Royal DSM (Netherlands), Johnson & Johnson (U.S.), Medtronic (U.S.), Cardinal Health (U.S.), Integra LifeSciences (U.S.), Smith & Nephew (U.K.), Medline (U.S.), Paul Hartmann AG (Germany), and BSN Medical (Germany).